Skip to Content

Synjardy Approval History

FDA Approved: Yes (First approved August 26, 2015)
Brand name: Synjardy
Generic name: empagliflozin and metformin
Dosage form: Tablets
Company: Eli Lilly and Company and Boehringer Ingelheim
Treatment for: Diabetes, Type 2

Synjardy (empagliflozin and metformin hydrochloride) is a sodium glucose co-transporter-2 (SGLT2) inhibitor and biguanide combination for the treatment of adults with type 2 diabetes.

Development History and FDA Approval Process for Synjardy

DateArticle
Dec 12, 2016Approval FDA Approves Synjardy XR (empagliflozin/metformin hydrochloride extended-release) for Adults with Type 2 Diabetes
Jul 19, 2016Approval FDA Expands Indication For Type 2 Diabetes Treatment Synjardy (Empagliflozin/Metformin Hydrochloride) To Include Treatment-Naïve Adults
Aug 27, 2015Approval FDA Approves Synjardy (empagliflozin/metformin hydrochloride) for Type 2 Diabetes
Oct 21, 2014U.S. FDA Accepts Filing Of NDA for Empagliflozin/Metformin Fixed-Dose Combination

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide